Literature DB >> 32694743

Soluble RANKL is physiologically dispensable but accelerates tumour metastasis to bone.

Tatsuo Asano1, Kazuo Okamoto2, Yuta Nakai1, Masanori Tsutsumi1, Ryunosuke Muro1, Ayako Suematsu1, Kyoko Hashimoto1, Tadashi Okamura3,4, Shogo Ehata5, Takeshi Nitta1, Hiroshi Takayanagi6.   

Abstract

Receptor activator of NF-κB ligand (RANKL) is a multifunctional cytokine known to affect immune and skeletal systems, as well as oncogenesis and metastasis1-4. RANKL is synthesized as a membrane-bound molecule, and cleaved into its soluble form by proteases5-7. As the soluble form of RANKL does not contribute greatly to bone remodelling or ovariectomy-induced bone loss8, whether soluble RANKL has a role in pathological settings remains unclear. Here we show that soluble RANKL promotes the formation of tumour metastases in bone. Mice that selectively lack soluble RANKL (Tnfsf11ΔS/ΔS)5-7,9 have normal bone homoeostasis and develop a normal immune system but display markedly reduced numbers of bone metastases after intracardiac injection of RANK-expressing melanoma and breast cancer cells. Deletion of soluble RANKL does not affect osteoclast numbers in metastatic lesions or tumour metastasis to non-skeletal tissues. Therefore, soluble RANKL is dispensable for physiological regulation of bone and immune systems, but has a distinct and pivotal role in the promotion of bone metastases.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 32694743     DOI: 10.1038/s42255-019-0104-1

Source DB:  PubMed          Journal:  Nat Metab        ISSN: 2522-5812


  21 in total

Review 1.  Mechanisms of RANKL delivery to the osteoclast precursor cell surface.

Authors:  Masashi Honma; Yuki Ikebuchi; Hiroshi Suzuki
Journal:  J Bone Miner Metab       Date:  2020-10-12       Impact factor: 2.626

2.  Stepwise cell fate decision pathways during osteoclastogenesis at single-cell resolution.

Authors:  Masayuki Tsukasaki; Nam Cong-Nhat Huynh; Kazuo Okamoto; Ryunosuke Muro; Asuka Terashima; Yoshitaka Kurikawa; Noriko Komatsu; Warunee Pluemsakunthai; Takeshi Nitta; Takaya Abe; Hiroshi Kiyonari; Tadashi Okamura; Mashito Sakai; Toshiya Matsukawa; Michihiro Matsumoto; Yasuhiro Kobayashi; Josef M Penninger; Hiroshi Takayanagi
Journal:  Nat Metab       Date:  2020-12-07

Review 3.  Role of RANKL in cancer development and metastasis.

Authors:  Kazuo Okamoto
Journal:  J Bone Miner Metab       Date:  2021-01-02       Impact factor: 2.626

Review 4.  Discovery of the RANKL/RANK/OPG system.

Authors:  Hisataka Yasuda
Journal:  J Bone Miner Metab       Date:  2021-01-03       Impact factor: 2.626

Review 5.  Mechanisms of joint destruction in rheumatoid arthritis - immune cell-fibroblast-bone interactions.

Authors:  Noriko Komatsu; Hiroshi Takayanagi
Journal:  Nat Rev Rheumatol       Date:  2022-06-15       Impact factor: 32.286

Review 6.  Osteoimmunology in Periodontitis: Local Proteins and Compounds to Alleviate Periodontitis.

Authors:  Kridtapat Sirisereephap; Tomoki Maekawa; Hikaru Tamura; Takumi Hiyoshi; Hisanori Domon; Toshihito Isono; Yutaka Terao; Takeyasu Maeda; Koichi Tabeta
Journal:  Int J Mol Sci       Date:  2022-05-16       Impact factor: 6.208

Review 7.  The osteocyte as a signaling cell.

Authors:  Jesus Delgado-Calle; Teresita Bellido
Journal:  Physiol Rev       Date:  2021-08-02       Impact factor: 37.312

Review 8.  Regulation of T cell-associated tissues and T cell activation by RANKL-RANK-OPG.

Authors:  Matthew C Walsh; Yongwon Choi
Journal:  J Bone Miner Metab       Date:  2021-01-12       Impact factor: 2.626

9.  RANKL and RANK in extracellular vesicles: surprising new players in bone remodeling.

Authors:  L Shannon Holliday; Shivani S Patel; Wellington J Rody
Journal:  Extracell Vesicles Circ Nucl Acids       Date:  2021-03-30

Review 10.  Role of Osteocytes in Cancer Progression in the Bone and the Associated Skeletal Disease.

Authors:  Manish Adhikari; Jesús Delgado-Calle
Journal:  Curr Osteoporos Rep       Date:  2021-04-05       Impact factor: 5.163

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.